Amgen Inc vs. Monte Rosa Therapeutics, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| AMGN | GLUE | |
|---|---|---|
| Market Cap | $205.32 billion | $1.03 billion |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | $-161,090,000 |
AMGN leads on 2 of 2 size & scale factors.
Valuation
| AMGN | GLUE | |
|---|---|---|
| P/E Ratio | 23.95 | — |
| Price / Book | 17.57 | 2.12 |
| Price / Sales | 5.39 | — |
GLUE leads on 1 of 1 valuation factors.
Profitability
| AMGN | GLUE | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | -33.06% |
AMGN leads on 1 of 1 profitability factors.
Dividend
| AMGN | GLUE | |
|---|---|---|
| Dividend Yield | 2.61% | — |
| Payout Ratio | 62.61 | — |
AMGN and GLUE split the dividend factors evenly.
Risk & Sentiment
| AMGN | GLUE | |
|---|---|---|
| Short Interest | 1.66% | 0.86% |
GLUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, GLUE overview, GLUE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.